title: The safety of statins in children.
abstract: Current American Academy of Pediatrics Guidelines recommended that statins should be considered as a first-line agent in children as early as 8 years of age. The aim of our work is to assess the safety of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in children with hypercholesterolaemia.
  
  
  CONCLUSIONS
  Controlled studies in children show that statin monotherapy is efficacious, well tolerated and safe in the short-time. Unfortunately, these studies have relatively short-term follow-up periods, and therefore, long-term safety remains unclear.
authors: Department of Cardiology, Mercato san Severino Hospital, Salerno, Italy. normanlamaida@libero.it
authors: Norman
authors: N
authors: Lamaida
authors: Ernesto
authors: E
authors: Capuano
authors: Laura
authors: L
authors: Pinto
authors: Eduardo
authors: E
authors: Capuano
authors: Rocco
authors: R
authors: Capuano
authors: Vincenzo
authors: V
authors: Capuano
mesh_terms: D000293:Adolescent; D000367:Age Factors; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002648:Child; D008078:Cholesterol, LDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000175:diagnosis* / Q000188:drug therapy*; D008019:Life Style; D008297:Male; D061214:Patient Safety; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Children; HMG-CoA reductase inhibitors; Safety